relevant to the contents of this paper to disclose.
Indeed, in the current report of the REPRISE II registry of 120 patients treated with the Lotus valve, deployment occurred successfully in 100% of patients without a single case of device migration, embolization, need for valve-in-valve therapy, or emergency cardiac surgery. The lone procedural death was due to cardiac perforation. Partial or complete retrieval was used during deployment in 32 patients (26.7%), and this ability certainly was a major factor in the remarkable procedural success reported in this study. 
